High-Grade Endometrial Carcinomas-Classification with Molecular Insights

摘要

This article provides an overview of the current diagnosis of endometrial carcinoma subtypes and provides updates, including the most recent molecular findings from The Cancer Genome Atlas and others. Interpretation of relevant immunohistochemistry and critical diagnostic differential diagnosis with pitfalls are discussed. Endometrial carcinoma is the most common gynecologic cancer in developed countries. Most women will survive this cancer and require only surgical management. However, women with high-grade carcinomas are at risk for recurrence and death. Thus, these patients can benefit from additional therapies. The molecular understanding of endometrial cancer has increased greatly in recent years and holds the promise of improving risk prediction and tailoring therapies. Although routine histology with a selected number of immunohistochemical markers is the current gold standard for diagnosis that guides clinical management, integration of molecular status into treatment decision-making is certainly in the future.